Clopidogrel
- Generic Name
- Clopidogrel
- Brand Names
- Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
- Drug Type
- Small Molecule
- Chemical Formula
- C16H16ClNO2S
- CAS Number
- 113665-84-2
- Unique Ingredient Identifier
- A74586SNO7
- Background
Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,
It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.
Clopidogrel was granted FDA approval on 17 November 1997.
- Indication
1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；
2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；
3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events
- Associated Therapies
- -
Ticagrelor Single Antiplatelet Therapy in Patients With High Risk of Bleeding After DCB for Coronary Small Vessel Disease
- Conditions
- Coronary Heart Disease
- Interventions
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Fu Wai Hospital, Beijing, China
- Target Recruit Count
- 292
- Registration Number
- NCT06088433
- Locations
- 🇨🇳
Fuwai Hospital, Beijing, Beijing, China
POPular GUILTY PILOT: Genotype-guided Clopidogrel Monotherapy
- Conditions
- Acute Coronary SyndromeCYP2C19 Polymorphism
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- St. Antonius Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT05926271
- Locations
- 🇳🇱
St. Antonius Hospital, Nieuwegein, Utrecht, Netherlands
Aspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor Stroke
- Conditions
- Ischemic Stroke
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Target Recruit Count
- 472
- Registration Number
- NCT05910125
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
Ticagrelor vs. Clopidogrel in Post PCI Patients
- Conditions
- Stable Chronic Angina
- Interventions
- First Posted Date
- 2023-05-15
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- Shiraz University of Medical Sciences
- Target Recruit Count
- 476
- Registration Number
- NCT05858918
- Locations
- 🇮🇷
Professor Kojuri Cardiology Clinic, Shiraz, Iran, Islamic Republic of
Pharmacodynamic Outcomes in CCS Patients Treated With an Individualized Treatment Strategy
- Conditions
- Coronary Artery DiseasePlatelet Reactivity
- Interventions
- Drug: CYP2C19 genotype guided P2Y12 monotherapyDrug: Clopidogrel
- First Posted Date
- 2023-03-17
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- St. Antonius Hospital
- Target Recruit Count
- 88
- Registration Number
- NCT05773989
- Locations
- 🇳🇱
St. Antonius Hospital, Nieuwegein, Utrecht, Netherlands
Anticoagulation Using Rivaroxaban on Top of Aspirin in Intracranial Atherosclerotic Stenosis
- Conditions
- Ischemic StrokeIntracranial AtherosclerosisStenosis
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Target Recruit Count
- 1180
- Registration Number
- NCT05700266
Body Weight Adjusted Clopidogrel Treatment in Patients With CORonary Artery Disease
- First Posted Date
- 2022-12-20
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- St. Antonius Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT05657041
- Locations
- 🇳🇱
StAntoniusH, Nieuwegein, Utrecht, Netherlands
🇳🇱St. Antonius Hospital, Nieuwegein, Netherlands
Multicentric Study on Clopidogrel Resistance in DAPT for CAS (MULTI-RESCLOSA)
- Conditions
- Clopidogrel, Poor Metabolism ofCarotid Stenosis
- Interventions
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- IRCCS Policlinico S. Donato
- Target Recruit Count
- 1140
- Registration Number
- NCT05566301
- Locations
- 🇮🇹
IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy
Impact of CYP2C19 Genotype-guided Clopidogrel and Ticagrelor Treatment on Platelet Function Test and Metabolomics Profile
- Conditions
- Coronary Artery Disease (CAD)
- Interventions
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Universiti Sains Malaysia
- Target Recruit Count
- 80
- Registration Number
- NCT05516784
- Locations
- 🇲🇾
Department of Cardiology, Penang General Hospital, George Town, Penang, Malaysia
A REAl-life Study on Short-term DAPT in Patients With Ischemic Stroke or TIA
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- University of L'Aquila
- Target Recruit Count
- 2239
- Registration Number
- NCT05476081
- Locations
- 🇮🇹
Neurology e Stroke Unit Departement, SS Filippo e Nicola Hospital, Avezzano, Abruzzo, Italy
🇮🇹Department of Neurology and Stroke Unit, Ente Ecclesiastico ospedale Generale Regionale Miulli, Acquaviva Delle Fonti, Italy
🇮🇹Department of Neurology, Murgia Hospital Fabio Perinei SS 96, Altamura, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.